Often, the patient cannot describe the sensations.These may be:

Sensations such as déjà vu (a feeling of familiarity), jamais vu (a feeling of unfamiliarity)
Amnesia of a single memory or set of memories
A sudden sense of unprovoked fear and anxiety
Nausea
Auditory, visual, olfactory, gustatory, or tactile hallucinations; olfactory hallucinations often seem indescribable to patients beyond "pleasant" or "unpleasant"
Visual distortions such as macropsia and micropsia
Dissociation or derealisation
Synesthesia (stimulation of one sense experienced in a second sense)
Dysphoric or euphoric feelings, fear, anger, and other emotionsFocal aware seizures are often called "auras" when they serve as a warning sign of a subsequent seizure. Regardless, an aura is actually a seizure itself, and such a focal seizure may or may not progress to a focal impaired awareness seizure. People who experience only focal aware seizures may not recognize what they are, nor seek medical care. Focal impaired awareness seizures
Focal impaired awareness seizures are seizures which impair consciousness to some extent: they alter the persons ability to interact normally with their environment. They usually begin with a focal aware seizure, then spread to a larger portion of the temporal lobe, resulting in impaired consciousness. They may include autonomic and psychic features present in focal aware seizures.Signs may include:
Motionless staring
Automatic movements of the hands or mouth
Confusion and disorientation
Altered ability to respond to others, unusual speech
Transient aphasia (losing ability to speak, read, or comprehend spoken word)These seizures tend to have a warning or aura before they occur, and when they occur they generally tend to last only 1–2 minutes.
Sitagliptin/simvastatin, sold under the brand name Juvisync, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes and hypercholesterolemia. It contains sitagliptin and simvastatin. Sitagliptin is a dipeptidyl peptidase-4 inhibitor  and simvastatin is an HMG-CoA reductase inhibitor. These two disorders commonly occur in people at the same time, and have been typically treated with administration of these medications separately. The combination was approved in 2011, and sold under the brand name Juvisync by Merck. Juvisync was later removed from the market in 2013, due to business reasons. History
In 1991, Merck & Cos simvastatin was approved as an HMG-COA inhibitor to lower the levels of LDL cholesterol. In 2006, Merck & Cos sitagliptin was approved by the FDA for treatment of diabetes mellitus type 2. Regulation
Juvisync was the first product to combine a cholesterol lowering drug with a type 2 diabetes drug in the same tablet. Nonclinical toxicology
Sitagliptin: Using male and female rats, a two-year carcinogenicity study was carried out with doses of 50, 150, and 500 mg/kg/day. The 500 mg/kg dose has exposure limits of 60 times what would be seen in the highest dose in humans. At this dose, liver adenoma/carcinoma was seen. Tumors were not seen from the smaller doses. Nomutagenic or clastogenic effects were seen from tests using several assays (CHO, rat, etc.). Fertility studies in rats showed no teratogenic effects.Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels.